Advertisement
Singapore markets closed
  • Straits Times Index

    3,300.34
    -2.85 (-0.09%)
     
  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     
  • Dow

    38,852.27
    +176.59 (+0.46%)
     
  • Nasdaq

    16,349.25
    +192.92 (+1.19%)
     
  • Bitcoin USD

    64,224.02
    -988.70 (-1.52%)
     
  • CMC Crypto 200

    1,332.60
    -32.53 (-2.38%)
     
  • FTSE 100

    8,299.47
    +85.98 (+1.05%)
     
  • Gold

    2,325.60
    -5.60 (-0.24%)
     
  • Crude Oil

    78.56
    +0.08 (+0.10%)
     
  • 10-Yr Bond

    4.4890
    -0.0110 (-0.24%)
     
  • Nikkei

    38,835.10
    +599.03 (+1.57%)
     
  • Hang Seng

    18,479.37
    -98.93 (-0.53%)
     
  • FTSE Bursa Malaysia

    1,605.68
    +8.29 (+0.52%)
     
  • Jakarta Composite Index

    7,123.61
    -12.28 (-0.17%)
     
  • PSE Index

    6,618.58
    -33.91 (-0.51%)
     

How This Pharma Company Can Benefit From Its Competitors

How This Pharma Company Can Benefit From Its Competitors

The race is on among pharmaceutical companies to obtain approval from the U.S. Food and Drug Administration (FDA) for new products serving the atopic dermatitis (AD, otherwise known as severe and chronic eczema) market. One of those companies, Incyte (NASDAQ: INCY), is coming off successful phase 3 trials of its ruxolitinib cream, but is now facing challenges brought on by delays in FDA approval.